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ABSTRACT
The nuclear factor of activated T-cells (NFAT) c1 has
been shown to be essential for Ca
2+-dependent
upregulation of myosin heavy chain (MyHC) I/b ex-
pression during skeletal muscle fiber type transform-
ation. Here, we report activation of extracellular
signal-regulated kinase (ERK) 1/2 in Ca
2+-ionophore-
treated C2C12 myotubes and electrostimulated
soleus muscle. Activated ERK1/2 enhanced NFATc
1-dependent upregulation of a  2.4kb MyHCI/b
promoter construct without affecting subcellular lo-
calization of endogenous NFATc1. Instead, ERK1/
2-augmented phosphorylation of transcriptional
coactivator p300, promoted its recruitment to
NFATc1 and increased NFATc1–DNA binding to a
NFAT site of the MyHCI/b promoter. In line, inhibition
of ERK1/2 signaling abolished the effects of p300.
Comparison between wild-type p300 and an
acetyltransferase-deficient mutant (p300DY) indi-
cated increased NFATc1–DNA binding as a conse-
quence of p300-mediated acetylation of NFATc1.
Activation of the MyHCI/b promoter by p300
depends on two conserved acetylation sites in
NFATc1, which affect DNA binding and transcrip-
tional stimulation. NFATc1 acetylation occurred in
Ca
2+-ionophore treated C2C12 myotubes or electro-
stimulated soleus. Finally, endogenous MyHCI/b
gene expression in C2C12 myotubes was strongly
inhibited by p300DY and a mutant deficient in ERK
phosphorylation sites. In conclusion, ERK1/2-
mediated phosphorylation of p300 is crucial for
enhancing NFATc1 transactivation function by
acetylation, which is essential for Ca
2+-induced
MyHCI/b expression.
INTRODUCTION
The nuclear factor of activated T-cells (NFAT) comprises
a family of ﬁve transcription factors, which are located in
a phosphorylated, inactive state in the cytoplasm of many
cell types including skeletal myotubes. Four members of
this family, NFATc1(2/c), NFATc2(1/p), NFATc3(4/x)
and NFATc4(3), are downstream targets of the Ca
2+-/
calmodulin-dependent phosphatase calcineurin (1,2).
During periods of elevated intracellular calcium concen-
tration ([Ca
2+]i), NFAT is dephosphorylated by calc-
ineurin, translocates into the nucleus, binds to consensus
DNA sites and stimulates gene transcription. Upon cessa-
tion of the Ca
2+-signal, termination of NFAT signaling
occurs through rephosphorylation of NFAT by protein
kinases, resulting in its retrograde translocation to the
cytoplasm (3,4). Several distinct sequences, including the
serine-rich region (SRR) and the serine–proline (SP)-rich
boxes, are not only important for NFAT regulation by
calcineurin, but are also major targets for phosphorylation
by various protein kinases (1).
Based on their contraction speed, force development,
fatigability and metabolic functions, skeletal muscle
ﬁbers have been classiﬁed into distinct ﬁber types (5).
The four different ﬁber types are characterized as
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oxidative/glycolytic (type IIA) and slow-twitch oxidative
(type I), which express myosin heavy chain (MyHC)
isoforms IIB, IID/X, IIA and I/b, respectively. In
response to altered physiological demands transformation
of ﬁber types occurs (6,7). The transformation process
includes functional, biochemical and morphological
changes of skeletal muscle cells which are a consequence
of different ﬁber type-speciﬁc gene expression patterns.
The resulting profound changes in muscle ﬁber type are
termed fast-to-slow or slow-to-fast transformation.
Elevations of [Ca
2+]i are thought to underlie fast-to-slow
shifts in muscle gene expression (8–10).
Calcineurin and the NFAT family member c1 are essen-
tial for the upregulation of MyHCI/b promoter activity
and mRNA expression during fast-to-slow transformation
of primary skeletal myotubes as well as C2C12 myotubes
(10–13). C2C12 myotubes have been previously shown to
be a suitable system for investigating ﬁber type transform-
ation (13–15). The differentiated C2C12 cells express a fast
ﬁber type-like character in terms of high expression of
endogenous fast MyHCIId/x protein and mRNA as well
as exogenous MyHCIId/x promoter activity, and low
expression of slow MyHCI/b protein and mRNA as well
as MyHCI/b promoter activity. The pattern of MyHC
expression and promoter activities can be switched
to a slow ﬁber type-like character (8,13,16) by
electrostimulation with a slow ﬁber type pattern, or by
addition of Ca
2+-ionophore A23187. As shown previous-
ly, the resting [Ca
2+]i of primary skeletal myotubes treated
with 0.1mMo fC a
2+-ionophore A23187 (10) tended to be
in the range of the resting [Ca
2+]i of the extensor digitorum
longus muscle, expressing mainly fast ﬁbers, when sub-
jected to low-frequency stimulation (17) to induce
fast-to-slow ﬁber transformation. Consistent with these
ﬁndings in cultured myotubes, calcineurin has been
shown to promote the slow muscle phenotype in animal
models (18–20), and NFATc1 has been identiﬁed as a key
transcription factor for the activity-dependent MyHCI/b
expression in slow-twitch soleus muscle (21). NFATc1 but
not c2 or c3 undergoes nuclear translocation in response
to increased intracellular Ca
2+-levels in primary skeletal
myotubes (22). We have previously demonstrated by
protein–DNA binding analysis a Ca
2+-ionophore-
inducible and calcineurin-dependent binding of NFATc1
to a NFAT consensus binding site within the proximal
MyHCI/b promoter that results in the subsequent recruit-
ment of transcriptional coactivator p300 in rabbit primary
skeletal myotubes (13).
NFATc1 is synthesized in six isoforms that differ in
their N- and/or C-termini due to two different promoter
and poly(A) site usage as well as alternative splicing events
(23,24). The N-terminal a peptide consists of 42 amino
acids while the N-terminal b peptide comprises 29 amino
acids. The NFATc1/A isoform contains a relatively short
C-terminus, whereas the isoforms NFATc1/B and C spans
longer extra C-terminal peptides. Consistent with other
members of the NFAT family, NFATc1/aA shares a
conserved central region that harbors an N-terminal
strong transactivation domain A (TAD-A) and a regula-
tory domain (Figure 7A). In addition, the DNA binding
domain shares >70% sequence homology among NFAT
proteins and <20% sequence homology to the DNA
binding domain of Rel/NF-kB factors, but it adopts a
very similar conformation and is thus designated as Rel
similarity (or homology) domain (RSD or RHD) (1,22).
The transcriptional coactivator p300 and its homolog,
the cAMP responsive element binding protein (CREB)-
binding protein (CBP) are both direct targets of cellular
signaling pathways, resulting in their post-translational
modiﬁcation (25). Several studies reported that their
function can be regulated by direct phosphorylation, and
phosphorylation sites have been identiﬁed (26–28).
Phosphorylation and activation of CBP and p300 by
extracellular signal-regulated kinase (ERK) 1/2 has been
demonstrated (29,30), with enhanced histone
acetyltransferase (HAT) activity resulting in the activation
of gene expression (31). Despite a high degree of
homology, CBP and p300 are not completely redundant
but display also unique roles (32). HATs are not only re-
sponsible for histone acetylation but can also acetylate a
variety of non-histone proteins including several transcrip-
tion factors (33). With regard to NFAT, p300/CBP were
shown to interact with different family members in vitro,
in T-cells and cardiomyocytes (34–37).
It has been demonstrated that increased [Ca
2+]i,
including membrane depolarization-induced rise in
[Ca
2+]i in neuronal and skeletal muscle cells, activates
mitogen-activated protein kinase (MAPK)/ERK kinase
1/2 (MEK1/2), the upstream kinase of ERK1/2, and
ERK 1/2 (38–40). Until now, only a limited number of
data available in the literature investigates ERK1/2 signal-
ing on myosin heavy-chain gene expression and shows
opposing effects. For example, during muscle regeneration
following muscle damage the onset of the Ras-MEK1/
2-ERK1/2 pathway promotes slow MyHCI/b gene expres-
sion (41). Other studies revealed that activated ERK2
downregulates a rat MyHCI/b promoter in the murine
C2C12 cell line while the same promoter construct was
not affected by ERK2 in slow type soleus or fast type
gastrocnemius muscle in rats (42). Thus, further studies
are needed to deﬁne the role of MEK1/2-ERK1/2 signal-
ing for ﬁber type-speciﬁc MyHC gene expression.
Concerning MyHCI/b expression, a possible relevance of
ERK1/2 on NFATc1 nuclear translocation has not been
investigated yet. So far, analysis on subcellular localiza-
tion, DNA binding and transactivation function of
different NFAT family members in T-cells and
cardiomyocytes revealed different modes of action of the
MEK1/2-ERK1/2 pathway on NFAT transcriptional
function depending on the kind of family member and
cell type (43–46).
The present article now investigates how activation of
the MEK1–ERK1/2-signaling pathway modulates the
NFATc1-dependent stimulation of MyHCI/b pro-
moter activity and gene expression induced by
increased intracellular Ca
2+. We demonstrate that
MEK1–ERK1/2 signaling induces the recruitment of
p300 to the MyHCI/b promoter and that acetylation of
NFATc1 by p300 is crucial for enhanced transcriptional
activity of NFATc1.
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Plasmid construction
The  2.4kb MyHCI/b and the  2.8kb MyHCIId/x
promoter luciferase reporter constructs have been desc-
ribed previously (13). To generate a 2.4kb MyHCI/b
promoter construct mutated in the  439/ 432-bp
NFAT consensus binding site (13), nucleotides from
 438 to  436 (GGA) were changed to TTC by using
the QuikChange II Site-Directed Mutagenesis Kit
(Stratagene) according to the manufacturer’s instructions.
Constitutively nuclear mutant NFATc1, NFATc1SRR,
lacking amino acids 180–183 (Ser180, Ser181, Arg182,
Ser183) in the SRR has also been described (13). The
NFATc1 isoform used here is the short isoform aA
(23,24). An c-Myc-His-tagged NFATc1 expression
vector was generated by subcloning NFATc1 from
pcDNA3–NFATc1, a gift from M. A. Brown (47), into
pcDNA3.1/Myc-His(-) (Invitrogen, Karlsruhe, Germany).
Single lysine-to-arginine (K-to-R) NFATc1 mutants
(K351R, K549R, K646R) were generated by PCR-based
site-directed mutagenesis using the Phusion Site-Directed
Mutagenesis Kit (New England Biolabs GmbH,
Frankfurt, Germany) according to the manufacturer’s in-
structions. Constitutively active mutant MEK1 (pMCL–
HA–MEK1–R4F, N3/S218E/S222D; MEK1ca)
and dominant negative mutant MEK1 (pMCL–HA–
MEK1-8E, K97M; MEK1dn) (48) were gifts from Dr
N. G. Ahn. The human wild-type p300 (pCMVb-p300-
Myc; p300wt) and the acetyltransferase-deﬁcient p300
mutant (pCMVb-p300DY-Myc; p300DY) (49) were gifts
from Dr T.-P. Yao. To generate p300 with mutations in
three possible ERK-speciﬁc phosphorylation motifs
(p300SA3, with serine residues 2279, 2315 and 2366 in
pCMVb-p300SA3-Myc replaced by alanine), again the
Phusion Site-Directed Mutagenesis Kit was used. The
CBP expression vector pRc/RSV-mCBP-HA (50) was
kindly provided by Dr R. H. Goodman.
Cell culture and transfections and luciferase reporter gene
assays
Mouse C2C12 myoblasts or HEK 293 cells were cultured
in growth medium (GM), consisting of complete
Dulbecco’s-modiﬁed Eagle’s medium with high glucose
(4.5g/l) (DMEM) (Invitrogen) supplemented with 10%
foetal bovine serum (FCS) (Sigma, Taufkirchen,
Germany), 2mM L-glutamine, 100U/ml penicillin and
100mg/ml streptomycin. C2C12 cells were transfected as
described previously (13), using 0.5mg of signal molecule
expression vector. Transfected cells were treated 24h post-
transfection with of 0.1mMC a
2+-ionophore A23187 and/
or 10mM of 1,4-bis[2-aminophenylthio]butadiene (U0126,
Sigma) for 2 days in differentiation medium (DM,
DMEM plus 5% horse serum). Transient transfections
of HEK 293 cells were performed at 50–80% conﬂuence.
Non-modiﬁed branched polyethylenimine (Sigma-
Aldrich) (4.5ml of a 1mg/ml solution) was added to a
mixture of 1.5mg DNA and 90ml serum- and antibiotics-
free DMEM, with subsequent addition of 900ml serum-
and antibiotics-free DMEM.
Luciferase reporter gene assays were described previ-
ously (13). Cells were cotransfected with pCMV-Gal as
an internal reference. The b-galactosidase activity was
determined by a standard colorimetric assay (51).
Alternatively, the Luminescent b-galactosidase Reporter
System 3 (Clontech, Takara Bio Europe, St Germain-
en-laye, France) was used according to the manufacturer’s
instructions with minor modiﬁcations.
RNA interference assays
C2C12 myoblasts transfected with MyHCI/b promoter
DNA and co-transfected with an expression vector
coding for constitutively nuclear NFATc1SRR or
empty expression vector pME18S, were additionally trans-
fected after 24h in GM with 0.825mg of a pool of double-
stranded 20–25nt siRNA that speciﬁcally targets mouse
p300 (siRNAp300) or a non-speciﬁc doublestranded
control siRNA (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA), using siRNA Transfection Reagent
(8ml/mg of respective siRNA; Santa Cruz Biotechnology,
Inc.) according to the manufacturer’s instructions. Cells
were grown for a further 2 days in DM.
Intracellular fractionation and western blot analysis
For intracellular fractionation, C2C12 cells transfected
with NFATc1SRR or the empty vector and grown for
2 days in DM in the presence or absence of 0.1mMC a
2+-
ionophore A23187 and/or 10mM U0126 were suspended
and incubated in cell fractionation buffer containing
5mM Tris–HCl (pH 7.4), 5mM KCl, 1.5mM MgCl2,
0.1mM EGTA, 1mM DTT, 0.2mM PMSF, 2mM
benzamidine and 5% (w/v) Trasylol for 5min. For cell
fractionation, 0.1% Nonidet P-40 (NP40) was added
into suspension. Cell extracts were centrifuged at 850g.
Pellet fraction was lysed in and aliquots of supernatant
fraction were added to gel loading buffer [160 mM Tris–
HCL, pH 6.8, 4% (w/v) sodium dodecyl sulphate (SDS),
20% (v/v) glycerol, 0.5% b-mercaptoethanol (v/v),
0.008% (w/v) bromophenol blue].
For western blot analysis, HEK 293 were lysed 2 days
and C2C12 cells 3 days post-transfection in 150ml of gel
loading buffer, and then incubated for 10min at 95 C.
Proteins were separated by SDS–PAGE as described pre-
viously (52), and blotted on a polyvinylidene diﬂouride
(PVDF) membrane (Sigma). Primary antibodies used
were anti-ERK2 (sc-81459), anti-histone H3 (sc-10809),
anti-NFATc1 (sc-13033), anti-p53 (sc-98), anti-p300
(sc-584), anti-c-Myc (sc-40), anti-a-tubulin (sc-8035)
(Santa Cruz Biotechnology, Inc.), anti-ERK1/2 (p44/42;
#9102), anti-phospho-ERK1/2 (Thr202/Tyr204; #9106),
anti-phospho-serine-MAPK/CDK (#2325) (Cell
Signaling, New England Biolabs), anti-acetylated-lysine
(ICP0380) (Immunechem, Burnaby, BC, Canada) and
anti-phospho-serine/threonine-proline (Ser/Thr-Pro,
minimal ERK consensus phosphoacceptor motif (53);
#05-368) (Upstate Biotechnologies, Millipore,
Schwalbach/Ts., Germany) antibodies. An anti-phospho-
serine-MAPK/cyclin-dependent kinase (CDK) antibody
chosen with regard to previously reported ﬁndings of
C-terminal serine phosphorylation of p300 by ERK2 in
Nucleic Acids Research, 2011,Vol.39, No. 14 5909keratinocytes (31) can detect MAPK but also CDK sub-
strates. The acetylation levels of c-Myc-tagged NFATc1
were determined in the presence of general histone
deacetylase (HDAC) inhibitors trichostatin A (TSA,
300nM; Sigma) and nicotinamide (NIA, 5mM; Sigma)
added 24h before lysis (HEK 293 cells) or present in the
lysis buffer (C2C12 myotubes). Bound antibodies were
detected with either anti-goat, anti-mouse or anti rabbit
IgG conjugated to horseradish peroxidase (HRP)
(Promega). Signals were visualized by enhanced chemilu-
minescence detection (Santa Cruz Biotechnology, Inc.)
with the LAS-3000 imaging system (Fujiﬁlm Europe
GmbH, Du ¨ sseldorf, Germany).
Immunoprecipitation assays
C2C12 myotubes from a 60-mm Petri dish were washed
twice with 200ml PBS, scraped, collected by centrifugation
and lysed in immunoprecipitation (IP) buffer (50mM
HEPES (pH 7.5), 1% Triton X-100, 10% (v/v) glycerol,
150mM NaCl, 1.5mM MgCl2, 1mM EGTA). Soleus
muscles were isolated from mice as described previously
(54) and immediately frozen in liquid nitrogen. Frozen
muscles were dounce-homogenized on ice in lysis buffer
with addition of complete protease inhibitor cocktail
(Roche Diagnostics GmbH, Mannheim, Germany) using
glass-on-glass homogenizer. For IP, pooled lysates from
eight equally treated muscles were used. Protein was quant-
itated using the Bradford assay (BioRad Laboratories
GmbH, Mu ¨ nchen, Germany). Nuclear extracts (2.5mg of
protein) were incubated overnight with 30ml of anti-p300
or anti-NFATc1 antibodies under gentle shaking at 4 C,
and subsequently incubated with 25ml of protein G
Sepharose (Amersham Biosciences Europe, Freiburg,
Germany) for 1.5h at 4 C. Immunoprecipitated beads
were pelleted and washed ﬁve times with cold washing
buffer (1x PBS containing 0.5% Nonidet P-40). Protein
was removed from the beads by boiling in 2  SDS
loading buffer for 5min and western blotting was
carried out using anti-phospho-serine-MAPK/CDK or
anti-NFATc1 antibodies.
In vitro kinase assay
Wild type p300 or mutant p300SA3 protein was incubated
in 20ml of kinase buffer [20 mM HEPES (pH 7.4), 10mM
MgCl2, 25mM NaCl, 5mM glycerol phosphate, 0.2mM
phenylmethylsulfonyl ﬂuoride, 1mM dithiothreitol,
0.1mM Na3VO4, 10mM ATP] at 30 C for 20min with
recombinant activated ERK2 (Sigma). About 0.2–2mgo f
substrate and 1mCi of [g-
33P] ATP (3000Ci/mmol) were
used. The reaction was stopped by adding an equal
volume of 5  SDS loading buffer and by heating at
95 C for 5min. After separation through 10% SDS–
PAGE, the gel was dried and radioactivity was visualized
by phosphorimaging using a Fuji Bas-1500 (Fujiﬁlm
Europe). For western blot analysis, a separate reaction
using non-radioactive ATP was run and the blot was
probed with anti-phospho-Ser/Thr-Pro, anti-p300 and
anti-ERK2 antibodies.
Immunoﬂuorescence studies
For detection of endogenous NFATc1, C2C12 myoblasts
were seeded on glass cover slips and cultured for 4 days in
DM. After 2 days cells were treated with 0.1mMC a
2+-
ionophore A23187 and/or 10mM U0126 for 2 days. For
detection of MyHCI/b gene expression, C2C12 myoblasts
transfected with 0.75mg of expression plasmid were grown
for 24h in GM and then for 3 or 4 days in DM in the
presence or absence of 0.1mMC a
2+-ionophore A23187.
Fixation and staining of cells were performed as described
previously (12), using primary goat polyclonal anti-
NFATc1 (Santa Cruz Biotechnology, Inc.), or mouse
anti-MyHCI/b antibodies (Sigma), and secondary ﬂuores-
cein isothiocyanate (FITC)-labeled antibodies (Santa Cruz
Biotechnology, Inc.). Nuclei were stained with DAPI
(Sigma). Stained cells were photographed on an inverted
ﬂuorescence microscope (Leica Microsystems, Wetzlar,
Germany; magniﬁcation  400).
Preparation of nuclear extracts and electrophoretic
mobility shift assays
C2C12 cells transfected with expression plasmids were
grown for 24h in GM and then for 3 days in DM with
or without Ca
2+-ionophore A23187 (0.1mM). Nuclear
extract preparation and EMSAs were performed as previ-
ously described (55). Oligonucleotides ( 448/ 423,
50-CTC CAG GCC AGG AAA GCA GGG AAA
TT-30) used as a probe contain a NFAT consensus binding
site of the rabbit slow MyHCI/b promoter (GenBank ac-
cession number AF192306) at  439/ 432 (13). In compe-
tition experiments, unlabeled annealed oligonucleotide
(200-fold excess) of self DNA was added. Antibody super-
shift assays were performed by pre-incubating nuclear
extracts (NEs) or in vitro translated NFATc1 with pre-
immune, or anti-NFATc1, or anti-p300, or anti-c-Myc
antisera (Santa Cruz Biotechnology, Inc.).
Semiquantitative reverse transcription PCR
Total RNA was isolated using NucleoSpin RNAII kit
(Macherey & Nagel, Du ¨ ren, Germany). mRNA was
reverse transcribed and cDNA ampliﬁed with Phusion
reverse transcription (RT)–PCR Kit (New England
Biolabs) according to the manufacturer’s instruction.
PCR was performed in a reaction of 50ml with
maximum cycle number of 35. PCR products were
analyzed by 2% agarose gel electrophoresis and visualized
with ethidium bromide staining. Primer pairs used were:
mouse MyHCI/b forward (F): 50-GCT GAG GCC CAG
AAA CAA G-30, and reverse (R): 50-TTC CAC GAT
GGC GAT GTT C-30; mouse MyHCIId/x F: 50-ACG
CTG GAT GCT GAG ATT AG-30, and R: 50-GAG
TGG TTC AGC TGG ATT TC-30; human p300 F: 50-A
TCAGCAGCGACTCCTTCAG-30, and R: 50-CAGATC
CTCTTCTGAGATGAGTT-30; mouse 18s rRNA F:
50-GGA CCA GAG CGA AAG CAT TT-30 and R:
50-TGC CAG AGT CTC GTT CGT TAT-30. PCR with
primers speciﬁc for 18s rRNA was performed for normal-
ization of transcript levels. The mRNA expression of
transfected Myc-tagged p300 expression vectors was
5910 Nucleic Acids Research, 2011,Vol.39, No. 14evaluated using a Myc-speciﬁc reverse and the p300
forward primer.
Muscle preparation and stimulation
Soleus muscles were isolated from mice as described pre-
viously (54). Pairs of solei were placed in bathing solutions
(120mM NaCl, 3.3mm KCl, 1.2mM MgSO4, 1.2mM
KH2PO4, 1.3mM CaCl2, 25mM NaHCO3, 100mg/
100ml glucose) equilibrated with 95% O2 and 5% CO2
immediately upon removal. The muscles were mounted
between an external force transducer (Harvard,
Bioscience 529503) and a rigid hook inside bathing
chambers to give isometric conditions. After initial equili-
bration of soleus muscle pairs in solution (120min), one of
the muscles was kept unstimulated in solution for the
entire duration of the experiment. The other muscle was
stimulated directly via platinum electrodes placed on
either side of the muscle for 30min with 15Hz (5s every
minute, pulse duration 1ms).
Multiple sequence alignment
Amino acid sequences of human NFATc1 (NP_765978),
NFATc2 (NP_036472), NFATc3 (NP_775186), and
NFATc4 (NP_001185894); mouse NFATc1
(NP_001157581), NFATc2 (NP_001129545), NFATc3
(NP_035031) and NFATc4 (NP_001161818); Bos taurus
NFATc1 (NP_001160087); Sus scrofa NFATc1
(NP_999326); Xenopus NFATc1 (NP_001085919); and
zebra ﬁsh NFATc1 (NP_001038624) were aligned with
MultAlin 5.4.1.
RESULTS
MEK1–ERK1/2 signaling increased
Ca
2+-ionophore-induced slow MyHCI/b
promoter activation
Previous studies indicate that the Ras-MEK1/2–ERK1/2
signaling pathway promotes MyHCI/b gene expression
during regeneration processes in slow-twitch soleus
muscles ﬁbers (41). To investigate a possible role of
MEK1–ERK1/2 signaling for MyHCI/b promoter regula-
tion, we used a genetic and a pharmacological approach.
U0126 (10mM), a speciﬁc inhibitor of direct upstream
activators of ERK1/2, MEK1/2, or overexpression of a
dominant-negative MEK1 (MEK1-8E, MEK1dn)
decreased, and overexpression of a constitutively active
MEK1 (MEK1–R4F, MEK1ca) increased basal activity
of a  2.4-kb MyHCI/b promoter luciferase reporter con-
struct (Figure 1, lanes 1, 3, 5 and 7), indicating an
activating impact of MEK1–ERK1/2 on the basal
promoter activity.
Consistent with a fast ﬁber type-like character of C2C12
myotubes in terms of MyHC isoform expression (13–15),
the slow MyHCI/b promoter has a lower activity in un-
treated myotubes compared with a  2.8-kb fast MyHCIId/x
promoter construct (Figure 1, lanes 1 and 9). Upregulation
of the low basal MyHCI/b promoter activity was induced
by treatment with 0.1mMC a
2+-ionophore A23187,
while MyHCIId/x promoter activity was diminished
(lanes 1, 2, 9 and 10), demonstrating a fast-to-slow trans-
formation on the level of MyHC promoter. MEK1ca
increased the MyHCI/b promoter activity in Ca
2+-
ionophore-treated C2C12 myotubes, whereas U0126 or
MMK1dn reduced the Ca
2+-ionophore-induced increase
(lanes 2, 4, 6 and 8). These data suggest a role for the
MEK1–ERK1/2 pathway in the upregulation of the
MyHCI/b promoter activity.
MEK1–ERK1/2 signaling increased
Ca
2+-ionophore-induced NFATc1 transcriptional
activity depending on a speciﬁc NFAT binding site
The importance of the transcription factor NFATc1 for
MyHCI/b promoter activation (13,21) led us to investigate
a possible interaction between MEK1-ERK1/2 signaling
and NFATc1. The short isoform NFATc1/aA was used
here in transient transfection assays (23,24). Although the
activating effect of 0.1mMC a
2+-ionophore on wildtype
(wt) MyHCI/b ( 2.4MyHCI/bwt) promoter activity was
further increased by overexpression of NFATc1 (Figure 2,
lanes 1, 3 and 4), the relatively moderate effect might
reﬂect the need for additional but endogenously limited
factor(s) for robust MyHCI/b promoter activation. A
putative NFAT binding site at  439/ 432bp in the
MyHCI/b upstream regulatory region had been previously
identiﬁed (13). When the  439/ 432-bp NFAT binding
site was mutated ( 2.4MyHCI/bNFATmut), no effect on
the basal MyHCI/b promoter activity was found in line
with NFATc1 not activating the wild-type promoter under
Figure 1. MEK1–ERK1/2 signaling increases Ca
2+-ionophore-induced
slow MyHCI/b promoter activation in C2C12 myotubes. C2C12 cells
were transiently transfected with a  2.4-kb MyHCI/b or with a
 2.8-kb MyHCIId/x promoter luciferase reporter construct alone or
cotransfected with expression vectors for constitutively active MEK1
(MKK1ca), or dominant negative MEK1 (MEK1dn), or empty vector.
Cells were grown for 24h in GM and then for 2 days in DM with or
without Ca
2+-ionophore A23187 (0.1mM) and/or U0126 (10mM). The
promoter activity is expressed as relative light units per unit
b-galactosidase (RLU/b-Gal). The data represent the mean±SD of
triplicate data points.
Nucleic Acids Research, 2011,Vol.39, No. 14 5911control conditions (Figure 2, lanes 1, 2 and 6). However,
the Ca
2+-ionophore-induced increase in promoter activity
was reduced in  2.4MyHCI/bNFATmut (lanes 1, 3, 6 and
7), indicating functional signiﬁcance of the  439/ 432-bp
NFAT binding site for MyHCI/b promoter activation.
The activating effect of MEK1ca coexpression on the
wild-type promoter activity under Ca
2+-ionophore was
abolished with  2.4MyHCI/bNFATmut (Figure 2, lanes
3, 5, 7 and 8), indicating that the NFAT binding site is
crucial for the activating effect of MEK1–ERK1/2
signaling.
The MEK1/ERK1/2 pathway activates the MyHCI/b
promoter via nuclear NFATc1
To investigate interaction between NFATc1 and MEK1–
ERK1/2 signaling without interfering with other factors
activated by Ca
2+-ionophore, we took advantage of
mutant NFATc1, NFATc1SRR (13). A deletion in the
regulatory SRR resulted in nuclear localization of trans-
fected NFATc1SRR in untreated fast ﬁber type-like
C2C12 myotubes, whereas endogenous NFATc1 was
almost exclusively cytoplasmic, as demonstrated by west-
ern blot and immunoﬂuorescence analysis [Figure 3A
(upper panel) and B]. The absence of a distinct NFATc1
band in western blots corresponds to the previously
reported existence of multiple phosphorylation states of
cytoplasmic and nuclear NFATc1 (56–58). In accordance
with the subcellular localization, NFATc1SRR, but not
wild-type NFATc1 (NFATc1wt) was able to activate the
MyHCI/b promoter in control cells (Figure 4A, lanes
1–3). Cotransfection of MEK1ca increased NFATc
1SRR-induced MyHCI/b promoter activity (lanes 1, 3
and 6). Conversely, addition of MEK1dn or inhibitor
U0126 (10mM) reduced NFATc1SRR-induced
MyHCI/b promoter upregulation (lanes 1, 3, 7 and 8).
Neither ERK1/2 inhibition via U0126 (10mM) nor activa-
tion via MEK1ca altered the subcellular localization of
endogenous NFATc1 (cytoplasmic) or transfected
NFATc1SRR (nuclear) in untreated C2C12 myotubes
[Figure 3A (compare lower with upper panel) and B].
Similarly, the nuclear translocation of endogenous
NFATc1 induced by 0.1mMC a
2+-ionophore was not
affected. The data show that MEK1–ERK1/2 signaling
is not affecting NFATc1 subcellular localization, but
exerts its activating function on MyHCI/b promoter
activity via nuclear NFATc1.
MEK1–ERK1/2 synergy with NFATc1 depends on
transcriptional coactivator p300
Using chromatinimmunoprecipitation, we previously
demonstrated NFATc1 binding to the  439/ 432-bp
site in the MyHCI/b promoter and recruitment of the tran-
scriptional coactivator p300 (13). Transfection of p300
wildtype (p300wt) caused a moderate increase of basal
MyHCI/b promoter activity in control and a further
increase in Ca
2+-ionophore-treated C2C12 myotubes
alone (Figure 4B, lanes 1–4). In addition, coexpression
of p300wt with NFATc1SRR in untreated cells further
increased the promoter activity as compared with NFATc
1SRR alone (Figure 4A, lanes 1, 3 and 4), indicating
that NFATc1-mediated MyHCI/b promoter activation
depends on an interaction with p300. Consistently,
mutating the NFAT binding site nearly abolished the
effect of p300 on the MyHCI/b promoter in
Ca
2+-ionophore-treated C2C12 myotubes (Figure 4B,
lanes 2, 4, 10 and 11). The data demonstrate MyHCI/b
promoter upregulation by p300, which is associated with
an intact  439/ 432-bp NFAT binding site.
Cotransfection with p300DY, a p300 mutant deﬁcient
in its acetyltransferase function, led to a reduction of the
Ca
2+-ionophore effect on MyHCI/b promoter activity,
abolishing also the effect of p300wt (Figure 4B, lanes 1,
2, 4 and 6). Moreover, p300DY almost completely abol-
ished the activating effect of cotransfection of NFATc
1SRR and p300 (Figure 4A, lanes 1 and 3–5). Thus,
the activating effect of p300 on the MyHCI/b promoter
correlates with the acetyltransferase function. Western
blot analysis demonstrated that the effect of exogenous
p300wt or p300DY was not associated with a change in
endogenous NFATc1 protein expression (Figure 4C).
Next, immunoblotting revealed a signiﬁcant decrease in
p300 protein expression in myotubes transfected with
speciﬁc p300 siRNA but not in cells transfected with
non-speciﬁc double-stranded control siRNA, or non-
transfected cells (Figure 4D). Knock-down of p300 led
to a small decrease in basal MyHCI/b promoter activity
and a reduction in the Ca
2+-ionophore-induced increase in
Figure 2. MEK1–ERK1/2 signaling increases Ca
2+-ionophore-induced
NFATc1 transcriptional activity depending on a speciﬁc NFAT binding
site. C2C12 cells were transiently transfected with a  2.4-kb wild-type
MyHCI/b ( 2.4 I/bwt) promoter construct or a  2.4-kb MyHCI/b
promoter construct mutated in the  439/ 432-bp NFAT binding site
( 2.4 I/bmut) alone, or were cotransfected with expression vectors for
NFATc1, or MEK1ca, or empty vector. Cells were grown for 24h in
GM and then for 2 days in DM with or without Ca
2+-ionophore
A23187 (0.1mM). The promoter activity is expressed as relative light
units per unit b-galactosidase (RLU/b-Gal). The data represent the
mean±SD of triplicate data points.
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activating effect of NFATc1SRR was also diminished
(lanes 1, 3, 4 and 6). These data further support a role
of p300 for NFATc1-mediated MyHCI/b promoter acti-
vation by Ca
2+-ionophore that depends on the intact
 439/ 432-bp NFAT binding site. The small effect of
p300 on MyHCI/b promoter basal activity may be due
to the interaction of p300 with transcription factors like
MyoD known to mediate the basal activity (13).
MEK1–ERK1/2 signaling indirectly regulates NFATc
1–p300 complex formation at the NFAT site via p300
We further examined whether DNA binding of NFATc1
is altered by MEK1–ERK1/2 signaling. NFATc1SRR
was comparably expressed in nuclear extracts (NEs)
from C2C12 myotubes not treated with Ca
2+-ionophore
(with endogenous NFATc1 nearly completely cytoplas-
mic, cf. Figure 3) used in electrophoretic mobility shift
assays (EMSAs) (Figure 5A, WB). No complex formation
was found with a probe containing the  439/ 432-bp
NFAT binding site and NE from untransfected control
cells (lane 1). Overexpression of NFATc1SRR led to
formation of two complexes, both supershifted (SS 1
and 2) by an anti-NFATc1 antibody but not preimmune
serum (PI) (lanes 2, 9 and 10), indicating binding of
NFATc1SRR to the probe. The faster mobility com-
plex (lower complex) was similar to that formed by the
binding of in vitro translated NFATc1 to the probe
(Figure 5B, lanes 1–3, 6 and 7, with supershift SS 1).
The slower mobility complex (upper complex) in
Figure 5A was similar to that observed when NE of un-
treated C2C12 myotubes was added to the in vitro
translated NFATc1 (Figure 5B, lane 4). An antibody
against p300 supershifted (SS 2) the upper complex
(lanes 4 and 8), indicating that the complex included en-
dogenous p300. Consistently, coexpression of NFATc
1SRR and p300wt led to increased formation of the
upper complex and disappearance of the lower complex
(Figure 5A, compare lanes 2 and 6). Thus, these data dem-
onstrate binding of NFATc1SRR alone to the probe in
the lower complex, presumably due to limited availability
of endogenous p300, and additional recruitment of p300
in the upper complex.
MEK1ca increased while U0126 (10mM) or MEK1dn
decreased upper complex formation, and lower complex
was reduced by MEK1ca while increased by U0126 or
MEK1dn (Figure 5A, lanes 2–5). An anti-p300 antibody
supershifted (SS 2) the upper complex completely while
leaving the lower complex unaffected, demonstrating
additional recruitment of p300 induced by activated
Figure 3. The MEK1-ERK1/2 pathway is not affecting NFATc1 subcellular localization. (A) Western blot analysis of the localization of endogenous
NFATc1 (empty vector) and transfected constitutively nuclear NFATc1SRR in C2C12 myotubes. C2C12 cells transfected with NFATc1SRR or
the empty vector were grown for 24h in GM and for 2 days in DM in the presence or absence (Control) of Ca
2+-ionophore A23187 (0.1mM) and/or
U0126 (10mM). After cell fractionation, aliquots of the pellet (nuclear, N) and supernatant (cytoplasmic, C) fraction were analyzed by western
blotting using anti-NFATc1 and anti-p53 antibodies. Detection of p53 serves as a control for nuclear localization. (B) Immunoﬂuorescence analysis
of the localization of endogenous NFATc1 in C2C12 myotubes. Cells transfected with MEK1ca expression vector were grown for 24h in GM and
then for 3 days in DM, untransfected C2C12 myotubes for 4 days in DM (Control) or for 2 days in DM and then for additional 2 days in DM in the
presence of Ca
2+-ionophore (0.1mM) and/or U0126 (10mM). Cells were stained with an anti-NFATc1-antibody. NFATc1 was visualized by a
FITC-labeled secondary antibody. Fluorescence was detected by using an inverted ﬂuorescence photomicroscope at a magniﬁcation of  400.
Nucleic Acids Research, 2011,Vol.39, No. 14 5913Figure 4. MEK1–ERK1/2 synergy with NFATc1 depends on transcriptional coactivator p300. C2C12 cells were transiently transfected with wildtype
 2.4kb MyHCI/b ( 2.4 I/bwt) promoter construct and cotransfected (A) with or (B) without expression vectors coding for wild-type NFATc1
(NFATc1wt), or constitutively nuclear NFATc1SRR, or empty vector. Cells were additionally cotransfected with expression vectors for wild-type
p300 (p300wt), or acetyltransferase-deﬁcient p300 (p300DY), or MEK1ca or MEK1dn, or empty vector. In (B) mutant (NFAT binding site)  2.4kb
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(continued)MEK1–ERK1/2 (lanes 2, 3 and 11). The data suggest that
complex formation of NFATc1SRR with p300 but not
binding of NFATc1SRR to the NFAT site per se was
augmented by activated MEK1–ERK1/2 signaling. In
line, the p300wt-induced increase in upper complex for-
mation was nearly abolished by coexpression of MEK1dn,
with additional reappearance of the lower complex (lanes
6 and 8). In addition, the limited amount of lower complex
formed in the presence of MEK1dn compared with the
much more intensive upper band in the absence of
MEK1dn (compare lanes 6 and 8) indicates that NFATc
1 alone has a limited afﬁnity to the NFAT site-containing
probe, while p300 obviously greatly increases the afﬁnity
of NFATc1 to the site. Furthermore, a decrease of the
upper complex and an additional increase of the lower
complex was observed when p300DY was coexpressed
with MEK1ca, compared with MEK1ca expression
alone (lanes 3 and 7), indicating that the acetyltransferase
function of p300 may also be important for NFATc
1SRR/p300 complex stability. Taken together, the data
suggest an effect of MEK1–ERK1/2 MAPK signaling on
complex stability of NFATc1SRR/p300 at the NFAT
site mediated by p300 (acetyltransferase activity) that
can account for MEK1–ERK1/2 and p300 action on
Figure 4. Continued
MyHCI/b ( 2.4 I/bNFATmut) promoter construct was also transfected. Cells were grown for 24h in GM and then for 2 days in DM with or
without U0126 (10mM), or Ca
2+-ionophore A23187 (0.1mM). (C) Western blot analysis of NFATc1 expression in Ca
2+-ionophore-treated C2C12
cells transfected with p300wt, p300DY or the empty vector, using an anti-NFATc1 antibody. The blot was reprobed with anti-a-tubulin antibody as
loading control. (D) Western blot analysis of p300 expression in non-transfected C2C12 myotubes, or cells transfected with a pool of double-stranded
20–25-nt siRNA that speciﬁcally target mouse p300 (siRNA p300), or with non-speciﬁc doublestranded control siRNA (siRNA control), using an
anti-p300 antibody. The blot was reprobed with anti-histone H3 antibody as loading control. (E) C2C12 cells were transiently transfected with a
 2.4-kb MyHCI/b promoter construct and cotransfected with NFATc1SRR or empty vector. After grown for 24h in GM, cells were cotransfected
with p300 siRNA (siRNA p300) or a non-speciﬁc control siRNA (siRNA control), and then grown for 2d in DM. The promoter activity in (A), (B)
and (E) is expressed as relative light units per unit b-galactosidase (RLU/b-Gal). The data represent the mean ± SD of triplicate data points.
Figure 5. MEK1–ERK1/2 signaling indirectly regulates NFATc1-p300 complex formation at the NFAT site via p300. EMSAs demonstrate that
NFATc1–p300 DNA binding complex stability depends on MEK1–ERK1/2 signaling. Radiolabeled oligonucleotide probes containing the  439/
 432-bp NFAT binding site from the MyHCI/b promoter were incubated (A) with nuclear extracts (NEs) from C2C12 myotubes grown for 3 days in
DM or (B) with in vitro translated NFATc1 or unprogrammed rabbit reticulocyte lysate (RL), with or without NEs from C2C12 myotubes grown for
3 days in DM. In (A) cells were transfected 24h prior NE preparation with or without constitutively nuclear NFATc1SRR expression vector alone,
or were cotransfected with expression vectors for MEK1ca, or MEK1dn or p300wt, or p300DY, or empty vector. In addition, cells were grown with
or without U0126 (10mM). In supershift experiments, preimmune serum (PI), or anti-NFATc1, or anti-p300 antibodies (Ab) were added. A 200-fold
excess of unlabeled wild-type competitor DNA (competitor+) was used in (B) for determination of speciﬁc protein–DNA binding reaction (lane 5).
After the incubation, samples were fractionated on 5% polyacrylamide gels. Complexes are indicated by an arrowhead. SS: supershift, with (A)
arrowhead 1 indicating the supershifted NFATc1SRR–probe complex, and arrowhead 2 indicating the NFATc1SRR/p300–probe complex and
(B) arrowhead 1 indicating the supershifted NFATc1–probe complex, and arrowhead 2 indicating the NFATc1/p300–probe complex. Probe: bottom
of the gel indicates excess probe. WB: western blot analysis of transfected NFATc1SRR in NEs by probing aliquots with an anti-NFATc1
antibody.
Nucleic Acids Research, 2011,Vol.39, No. 14 5915NFATc1 transcriptional function and hence for MyHCI/b
promoter upregulation as found in transient transfection
assays (cf. Figures 1, 2 and 4).
MEK1–ERK1/2 signaling-dependent p300 phosphorylation
in vivo and in vitro
We then investigated whether p300 can be a substrate of
ERK1/2 in C2C12 myotubes. Protein immunoprecipitated
from cell lysates with anti-p300 antibodies was immuno-
blotted with antibodies speciﬁc for phospho-serine (p-Ser)
followed by proline (Pro), a sequence motif found in
MAPK or cyclin-dependent kinase (CDK) substrates.
The level of p300 serine phosphorylation (p300-p-Ser)
was increased in C2C12 myotubes treated with 0.1mM
Ca
2+-ionophore compared with untreated cells
(Figure 6A). MEK1ca further increased p300-p-Ser
levels in Ca
2+-ionophore-treated C2C12 myotubes,
whereas MEK1dn or 10mM U0126 nearly abolished the
Ca
2+-ionophore effect. These results indicate that the
Ca
2+-ionophore-induced activation of MEK1–ERK1/2
signaling increases the proline-directed phosphorylation
of p300. To conﬁrm that p300 can be direct substrate of
ERK, an in vitro kinase assay was performed. Wild-type
p300 protein was phosphorylated by recombinant
activated ERK2 in vitro as detected by anti-p-Ser/
Threonine (Thr)-Pro antibodies (Figure 6B), demonstrat-
ing that ERK2 can phosphorylate p300. In addition,
autophosphorylation of the kinase (p-ERK2) is often
observed in this kind of assay. Previous data indicate
that the ERK-speciﬁc phosphorylation motif features
serine–proline or threonine–proline phosphorylation sites
in the vicinity of an ERK binding site (Phe-Xaa-Phe-Pro)
(59). Phosphorylation by ERK2 was reduced in p300SA3,
a mutant with serine residues 2279, 2315 and 2366 being
replaced by alanine (Figure 6B). These sites play major
roles in epidermal growth factor (EGF)-induced ERK2-
mediated phosphorylation of p300 in keratinocytes (28).
Taken together, these data indicate that p300 is a direct
target of MEK1-ERK1/2 signaling via serine-
phosphorylation by ERK1/2 in Ca
2+-ionophore-treated
C2C12 myotubes.
MEK1–ERK1/2 signaling-dependent p300 phosphorylation
induces NFATc1 acetylation in HEK 293 cells
The functional importance of p300 acetyltransferase
function for NFATc1-dependent MyHCI/b promoter ac-
tivation prompted us to investigate the possible acetyl-
ation of NFATc1 by p300. Lysine (K)-acetylation of
Myc-tagged NFATc1 (NFATc1-K-Ac) was detected,
when p300wt but not when p300DY was coexpressed in
HEK 293 cells (Figure 6C). In contrast to p300wt, expres-
sion of CBP led to a much smaller increase in the level of
NFATc1-K-Ac. Lysine acetylation of NFATc1 was fur-
ther increased by coexpression of MEK1ca and p300wt
(Figure 6D). In addition, MEK1ca robustly increased
the small level of basal ERK1/2 phosphorylation (see
1min exposure time in Figure 6D), indicating activation
without changes in the level of total ERK1/2 expression.
In contrast, coexpression of MEK1dn abolished ERK1/2
phosphorylation and severely reduced NFATc1 lysine
acetylation. The activating effect of MEK1ca on NFATc
1-K-Ac but not on ERK1/2 phosphorylation was abol-
ished by coexpression of p300DY. Taken together, the
data demonstrate that p300 can acetylate NFATc1, and
acetylation is MEK1–ERK1/2-dependent.
MEK1–ERK1/2 signaling-dependent p300 phosphorylation
induces NFATc1 acetylation in C2C12 myotubes and
soleus muscle
In C2C12 myotubes treated with 0.1mMC a
2+-ionophore,
a small amount of acetylation of endogenous NFATc1
could be detected as compared with untreated myotubes
(Figure 6E). Increased acetylation of endogenous NFATc
1 was found in cells treated with Ca
2+-ionophore and
overexpressing p300wt, indicating the ability of p300 to
acetylate endogenous NFATc1. The level of NFATc
1-K-Ac was also increased by overexpressing Myc-
tagged NFATc1 alone and further enhanced by co-
expression of p300wt. Western blot analysis revealed an
increase in ERK1/2 phosphorylation in Ca
2+-ionophore-
treated myotubes, while total ERK1/2 expression was not
altered, indicating stimulation of MEK1–ERK1/2 signal-
ing by Ca
2+-ionophore (Figure 6E). U0126 (10mM) in-
hibited ERK1/2 activation as demonstrated by abolished
phosphorylation of ERK1/2, and blocked lysine acetyl-
ation of NFATc1 in Ca
2+-ionophore-treated cells co-
expressing NFATc1 and p300wt. Together, the results
indicate that the Ca
2+-ionophore-induced phosphoryl-
ation of p300, which is dependent on activated ERK1/2
signaling, mediates acetylation of NFATc1 in vivo.
To test whether NFATc1 lysine acetylation can occur in
whole muscle, mouse soleus was stimulated. Mouse soleus
has in contrast to other species a signiﬁcant (nearly 50%)
proportion of fast ﬁbers (60). When isolated soleus was
stimulated for 30min with 15Hz, an increase of nuclear
NFATc1 was found (Figure 6F), in accordance with
previous ﬁndings in isolated ﬁbers from fast ﬂexor
digitorum brevis in culture using a similar pattern (61).
Stimulation also increased the level of total lysine-
acetylated NFATc1 as well as the level relative to
nuclear NFATc1 (Figure 6G). Furthermore, activation
of ERK1 and 2 was enhanced by stimulation, as demon-
strated by increased phosphorylation, while total ERK1/2
expression was not altered (Figure 6F). The data show
that activity-dependent ERK1/2 activation and NFATc1
lysine acetylation can both occur in whole muscle.
Identiﬁcation of acetylation sites in NFATc1 and effects
on transactivation function and DNA binding
To prove that acetylation of NFATc1 is indeed mediated
by p300, we searched for relevant acetylation sites in
NFATc1/aA. The spectrum of modiﬁcations potentially
affecting a given lysine residue is deﬁned by the
presence/absence of several adjacent residues, including a
glutamic acid, a proline, and/or a serine–proline motif.
For example, a G/SKXXP motif has been shown to be a
consensus site for the acetylation of the Brm proteins by
CBP/p300 (62) while Sp3 acetylation occurs at a motif that
contains three glutamic acid residues, KEEEP (63) We
identiﬁed two potential acetylation sites, lysines 351 and
5916 Nucleic Acids Research, 2011,Vol.39, No. 14Figure 6. NFATc1 is acetylated by p300 in a MEK1–ERK1/2-dependent manner. (A) Analysis of p300 phosphorylation by IP and western blot.
C2C12 cells were transfected with MEK1ca, or MEK1dn, or empty vector. After 24h in GM cells were further grown in DM. Two days after
transfection cells were pretreated with or without U0126 (10mM) for 30min, followed by treatment with Ca
2+-ionophore A23187 (0.1mM) for 3h.
Protein from cell lysates was immunoprecipitated (IP) with anti-p300 antibody. Phosphorylation of p300 was analyzed using an anti-phospho-serine
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(continued)549 (K351, K549) as part of a KXEP and KXE motif,
respectively, and compared those with lysine 646 (K646),
not comprising such a motif (Figure 7A). K351 is located
in the regulatory and K549 as well as K646 in the RSD
domain. We generated mutants by replacing lysine
residues with arginine and transfected C2C12 cells with
Myc-tagged wild-type NFATc1/aA and mutants to test
if acetylation can occur in vivo (Figure 7B). Acetylation
of wild-type NFATc1/aA in the presence of p300 and
Ca
2+-ionophore was clearly detected. Compared to
wild-type, acetylation of the K351R and K549R mutants
was signiﬁcantly impaired while no signiﬁcant decrease in
acetylation occurred for the K646R mutant. By utilizing
these NFATc1/aA mutants, we tested whether or not p300
activates the MyHCI/b promoter through NFATc1
acetylation. MyHCI/b promoter activation was reduced
by the acetylation-defective NFATc1/aA mutants
K351R and K549R, but not by K646R when compared
to wild-type in Ca
2+-ionophore treated cells coexpressing
p300wt (Figure 7C). Thus, we conclude that K351 and
K549 are major acetylation sites and that p300 is acting
on the MyHCI/b promoter via acetylation of NFATc1/aA
rather than merely being recruited to acetylate nucleosom-
al tails of histones.
We also tested whether acetylation affects NFATc1
DNA binding. Using the NFAT binding site probe
(Figure 5), complex formation in nuclear extracts from
Ca
2+-ionophore-treated C2C12 cells expressing Myc-His-
tagged wild type or mutant NFATc1/aA together with
p300wt was analyzed by EMSA. Two NFATc1-speciﬁc
complexes were detected: one containing mainly the en-
dogenous NFATc1 (complex I) and one containing mainly
the exogenously transfected Myc-NFATc1/aAwt
(complex II) (Figure 7C, lane 2). The speciﬁcity of
complex formation was veriﬁed both by competition
with a 200-fold excess of cold probe (lane 5) and by
supershifting only complex II using an anti-c-Myc
antibody (lane 6). Importantly, lesser complex II forma-
tion together with unchanged complex I formation was
found with NFATc1/aAK351R and K549R,
demonstrating that both mutants had a lower DNA
binding activity than wild-type. These ﬁndings can
account for an acetylation-mediated increase in NFATc1
afﬁnity to the MHCI/b promoter and NFATc1-mediated
transcriptional activation.
Interestingly, multiple sequence alignment revealed that
one acetylated lysine in murine NFATc1 (K351) and
adjacent amino acids are fully conserved in NFATc1 of
boar, bovine, ﬁsh, frog, human and mouse origin, and in
NFATc3 of mouse and human origin (Figure 7E, in blue).
The second major acetylated lysine (K549) and adjacent
amino acids are fully conserved in NFATc1-4 of boar,
bovine, ﬁsh, frog, human and mouse (Figure 7E, in red).
Ca
2+-ionophore-induced MyHCI/b gene expression
depends on phosphorylation of p300 and its
acetyltransferase function
We further assessed the effect of p300 on endogenous
MyHCI/b mRNA and protein levels in C2C12 myotubes
by semiquantitative RT–PCR and immunoﬂuorescence
analysis. Low levels of MyHCI/b and high levels
MyHCIId/x mRNA were detected in untreated cells
(Figure 8A). Ca
2+-ionophore (0.1mM) decreased
MyHCIId/x mRNA and increased MyHCI/b mRNA
and protein (Figure 8B and C) levels, demonstrating the
fast-to-slow transformation at the mRNA level. A further
increase in expression of MyHCI/b mRNA and protein
was apparent in cells transfected with p300wt while
p300DY completely and p300SA3 largely abolished the
Ca
2+-ionophore-induced increase. Thus, the activating
effect of p300 on MyHCI/b endogenous gene expression
correlates with its acetyltransferase function, in line with
data on promoter activity (Figure 4B), and depends at
least in part on the phosphorylation of serines 2279,
2315 and 2366. Taken together, the results implicate that
ERK-dependent serine phosphorylation of p300 is a regu-
latory mechanism pivotal for a strong MyHCI/b gene ex-
pression induced by increased intracellular Ca
2+-levels.
Furthermore, decreased MyHCIId/x mRNA levels in
Ca
2+-ionophore-treated C2C12 cells were unaffected by
p300wt, p300DY or p300SA3, suggesting that
downregulation of MyHCIId/x expression was not
mediated via p300.
DISCUSSION
In the present study, the role of MEK1–ERK1/2 signaling
pathway and transcriptional coactivator p300 in
regulating NFATc1-dependent slow MyHCI/b promoter
activity and endogenous gene expression was investigated.
Figure 6. Continued
(p-Ser) MAPK/CDK antibody, and p300 protein expression was detected by reprobing with an anti-p300 antibody. (B) In vitro kinase assay with
p300wt or p300SA3 incubated with recombinant activated ERK2. The phosphorylation level of p300 was analyzed by western blot using
anti-phospho-Ser/Thr-Pro antibodies. The input of proteins was analyzed with anti-p300 and anti-ERK2 antibodies. Analysis of NFATc1 lysine
acetylation and ERK1/2 activation in (C) and (D) HEK 293 cells; (E) C2C12 myotubes; and (F) mouse soleus muscle by western blot (WB). In (C–E)
HEK 293 or C2C12 cells were transiently transfected with or without NFATc1-c-Myc expression vector alone, or with p300wt, or p300DY, or CBP,
or MEK1ca, or MEK1dn, or empty vector. HEK 293 cells were then grown for 2 days in GM, C2C12 cells for 24h in GM and for 2 days in DM.
HDAC inhibitors (300nM TSA and 5mM NIA) were added 24h before lysis in (C) and (D) and to the lysis buffer in (E). C2C12 myotubes were
grown in the presence or absence of Ca
2+-ionophore (0.1mM) and/or U0126 (10mM) for 12h before lysis. (F) Isolated mouse soleus muscles were
electrostimulated (30min, 15Hz; + stimul) or not stimulated (  stimul). Eight solei were pooled per each group and proteins were immunopre-
cipitated (IP) from nuclear extracts with anti-NFATc1 antibodies. Expression of Myc-tagged NFATc1 was monitored by an anti-c-Myc antibody,
and NFATc1 lysine acetylation was detected by using an anti acetyl-lysine antibody (K-Ac). Expression of endogenous NFATc1 was analyzed by
reprobing with an anti-NFATc1 antibody. Expression of phosphorylated ERK1 and 2 (p-ERK1 and 2) was analyzed using anti-phospho-ERK1/2
antibodies, and expression of total ERK1 and 2 with anti-ERK1/2 antibodies, directly analyzed from cell lysates in (F). Exposure times for enhanced
chemiluminescence detection with the LAS-3000 imaging system in (D) were 10s or 1min. Detection of a-tubulin served as a loading control.
Molecular weights are indicated. (G) Band intensities from western blot analysis as shown in (F) were normalized to a-tubulin and presented as mean
of 2 and single values (open circle).
5918 Nucleic Acids Research, 2011,Vol.39, No. 14Figure 7. Identiﬁcation of lysine residues of NFATc1/aA acetylated by p300. (A) Structure of NFATc1/aA. NFATc1/aA is one of the six NFATc1
isoforms which differ in their N- and/or C-termini due to two different promoter and poly(A) site usage as well as alternative splicing events. The
structure shows the NFAT-homology region that comprises the amino-terminal transactivation domain (TAD), the calcineurin binding site (CaN),
the nuclear localization sequence (NLS), the nuclear exit sequence (NES), the serine-rich regions SRR1 and 2, as well as the SP1, SP2 and SP3 motifs
(Ser-Pro rich) that are targeted by maintenance and export kinases. The Rel similarity (or homology) domain (RSD or RHD) comprises the DNA
binding motif. Sequences containing possible acetylation sites, lysines 351, 549 and 646 (K351, K549 and K646), investigated in this study are shown
below. (B) C2C12 cells were transfected with Myc-tagged NFATc1/aAwt, or mutant NFATc1/aA K351R, or K549R, or K646R, or empty vector,
respectively, and cotransfected with p300wt or empty vector. Cells were grown for 24h in GM and then for 4 days in DM with Ca
2+-ionophore
A23187 (0.1mM). Cell lysates were probed with anti-K-Ac and anti-NFATc1 antibodies. Exposure times for enhanced chemiluminescence detection
were indicated. Longer exposure times (2 and 3min) demonstrate endogenous NFATc1 and NFATc1-K-Ac levels in cells transfected with empty
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(continued)We previously found that increased [Ca
2+]i in primary
skeletal muscle cells induces the recruitment of p300 to
NFATc1 bound to the MyHCI/b promoter (13). The
main ﬁndings presented now about a mechanism of sig-
naling leading to slow ﬁber-speciﬁc gene expression are
summarized in a model (Figure 9). Brieﬂy (i) phosphoryl-
ation of p300 via MEK1-ERK1/2 signaling is a major
effect caused by elevated [Ca
2+]i; (ii) phosphorylation of
p300 stimulates its binding to NFATc1; (iii) binding of
p300 promotes lysine acetylation of NFATc1; and (iv)
enhances NFATc1 interaction with and transactivation
of the MyHCI/b promoter.
HATs like p300 or CBP not only acetylate histones but
also target a variety of non-histone proteins including
several transcription factors (33). For example, HAT
activity of p300 was shown to be crucial for transactiva-
tion of the keratin 16 promoter. The C-terminus of the
transcription factor c-Jun, which plays an important role
for keratin 16 expression, can be acetylated by p300 (64).
During myogenesis, acetylation of myocyte enhancer
factor 2 (MEF-2) by p300 enhances the transcriptional
activity by increasing DNA binding activity (65). Here,
the acetyltransferase function of p300 is shown to be im-
portant for NFATc1 acetylation and subsequent MyHCI/
b promoter activation by NFATc1 in myotubes, at least in
part by sustaining complex formation at the NFAT
binding site of the promoter. Transcription factor
binding to DNA is thought to be affected by acetylation
presumably through conformational changes (65). In
addition to these ﬁndings in skeletal myotubes, p300
also affects the expression of MyHCb in cardiomyocytes.
A previous study showed that oncogene E1A-mediated
transcriptional repression of MyHCb promoter activity
in primary cardiomyocytes was relieved by overexpression
of p300 (66).
Besides possessing intrinsic HAT activity, p300/CBP
can also mediate the transactivation function of transcrip-
tion factors to enhance gene transcription via creating a
bridge between transcription factors and the basal tran-
scription machinery, or acting as a scaffold for the
assembly of multiprotein complexes, including transcrip-
tion factors and cofactors (67). The latter two functions
may also contribute to p300 induced increases in NFATc1
transcriptional activity. In accordance with data presented
in skeletal myotubes, the mechanism underlying increased
NFAT transcriptional activation function is also achieved
through interaction with transcriptional coactivators in
other cell types. Both the N-terminal and the C-terminal
TAD of NFATc4 are necessary for interaction with CBP
in COS cells, and potentiation of NFATc4 transcriptional
activity was meditated by CBP (68). In cardiomyocytes,
p300 markedly potentiates the binding of NFATc1 to the
B cell leukemia-2 (bcl-2) NFAT element by interacting
with NFATc1 (69). The N-terminal TAD, TAD-A, of
NFATc1 and c2 binds p300/CBP and enhances TAD-A
activity in T-cells (34,35). Complex formation of p300
with NFATc1 in myotubes was previously shown by us
(13). Here, we provide further elucidation of the mechan-
ism revealing that p300-mediated lysine acetylation of
NFATc1 is at least one factor that markedly increases
NFATc1-dependent transactivation function. Our data
do not exclude acetylation of other proteins such as
histones by p300 that may synergize in regulating NFAT
function during skeletal muscle ﬁber transformation.
The functional cooperation between cofactors and tran-
scription factors can require phosphorylation of the tran-
scription factor (29,70). Several NFAT family members
have phosphorylation sites for protein kinases, including
MAPKs, within the NH2-terminal domain (1,44). The
NFATc1–TAD-A was at least shown to be an in vitro
target of ERK2, and ERK2 increased TAD-A activity in
T-cells (35). Moreover, MEK1 overexpression has been
shown to increase NFATc3 DNA binding in
cardiomyocytes, with NFATc3 directly phosphorylated
by activated ERK2 (44). In addition to this direct effect,
indirect enhancement of NFAT-dependent gene expres-
sion occurs through induction of AP-1 activity via
MEK1–ERK1/2 signaling. Our data do not rule out phos-
phorylation of NFATc1 by MEK1–ERK1/2 signaling in
the C2C12 myotubes, but are in favor of the phosphoryl-
ation of p300 with subsequent acetylation of NFATc1.
Clearly, the role of MEK1–ERK1/2 is not to function as
a regulator of NFATc1 nuclear shuttling.
Indeed, coactivators like p300 or CBP themselves are
controlled by an array of various covalent modiﬁcations,
leading to changes in HAT activity or protein–protein
interactions (71). Direct phosphorylation of p300/CBP
can control their recruitment to the transcriptional
complex (27,72), and a number of phosphorylatable, evo-
lutionary conserved residues are present in p300 and CBP.
As several different phosphorylation sites are available to
MAPKs (67,73), phosphorylation and subsequent
Figure 7. Continued
vectors. The expression levels of the transfected Myc-tagged NFATc1wt and mutants were detected by immunoblotting with anti-c-Myc-antibody.
(C) C2C12 cells were transiently transfected with a  2.4-kb MyHCI/b promoter construct and cotransfected with expression vectors coding for
Myc-tagged wild-type NFATc1aA (NFATc1aAwt), or mutant NFATc1aA K351R, or K549R, or K646R, or empty vector. Cells were additionally
cotransfected with expression vectors for wild-type p300 (p300wt) or empty vector. Cells were grown for 24h in GM and then for 2 days in DM with
or without Ca
2+-ionophore A23187 (0.1mM). The promoter activity is expressed as relative light units per unit b-galactosidase (RLU/b-Gal). The
data represent the mean ± SD of triplicate data points. (D) EMSA demonstrates that acetylation-defective NFATc1/aA mutants have reduced
DNA-binding activity. Nuclear extracts from C2C12 myotubes transfected with Myc-His-tagged NFATc1/aAwt, or K351R, or K549R mutants (all
expressed at similar levels, as revealed by western blot analysis with anti-c-Myc-antibody) and grown for 3 days in DM in the presence of Ca
2+-
ionophore were mixed with an excess of radiolabeled or cold competitor NFAT probe. After incubation, samples were fractionated at 4 C on a 3.0%
nondenaturing polyacrylamide gel for 2h at 33mA. Complexes are indicated by an arrowhead. Ab, antibody; SS, supershift. (E) NFATc1 isoforms
and other members of the NFAT family from several vertebrates were aligned using MuliAlign 5.4.1 to show sequences including the two functional
important lysines (equivalent to K351 and K549 in murine NFATc1), which can be acetylated by p300, and lysine 646 (K646), which is not
acetylated. Blue, conserved amino acids in at least all NFATc1 of several vertebrates; red, conserved amino acids in all members of the NFAT
family. b, Bos taurus (bovine); h, human; m, mouse; s, Sus scrota (boar); x, Xenopus; z, zebra ﬁsh.
5920 Nucleic Acids Research, 2011,Vol.39, No. 14Figure 8. Ca
2+-ionophore-induced MyHCI/b gene expression depends on phosphorylation of p300 and its acetyltransferase function. (A)
Semiquantitative RT–PCR analysis of endogenous MyHCI/b and IId/x expression. Total RNA was isolated from C2C12 cells transfected with
p300wt-, or p300DY-, or p300SA3-Myc, or empty Myc-tag expression vector. Cells were grown for 24h in GM and then for 2 days in DM with or
without Ca
2+-ionophore. PCR products were separated on a 2% agarose gel and visualized with ethidium bromide staining. 18s rRNA levels were
used for normalization. The mRNA expression of transfected Myc-tagged p300, p300DY and p300SA3 was evaluated using a Myc-speciﬁc reverse
and a p300 forward primer. (B) Immunoﬂuorescence analysis of endogenous MyHCI/b expression in C2C12 myotubes. C2C12 cells were transiently
transfected with p300wt-, or p300DY-, or p300SA3-Myc, or empty Myc-tag expression vector. Cells were grown for 24h in GM and then for 4 days
in DM with or without Ca
2+-ionophore A23187 (0.1mM). Cells were stained with an anti-MyHCI/b-antibody. MyHCI/b was visualized by a
FITC-labeled secondary antibody. Fluorescence was detected by using an inverted ﬂuorescence photomicroscope. MyHCI/b positive cells appear
green. Nuclei were stained with DAPI. Scale bar, 100mm. (C) Histogram illustrating the mean number of MyHCI/b positive cells per vision ﬁeld
(n=6) as examined by immunoﬂuorescence analysis shown in (B). Western blot analysis using anti-c-Myc antibody illustrating p300 expression levels
in cells transfected with Myc-tagged p300 expression vectors.
Nucleic Acids Research, 2011,Vol.39, No. 14 5921activation of CBP by MAPKs (29) including ERK1 have
been shown, resulting in stimulation of HAT enzymatic
activity (74). EGF-dependent C-terminal serine phosphor-
ylation by ERK2 regulates recruitment of p300 to the
keratin 16 promoter in an epidermal keratinocyte cell
line, thereby stimulating acetyltransferase activity and
interaction with transcription factor Sp1 (31). We have
now demonstrated that phosphorylation of serine
residues in ERK-speciﬁc phosphorylation motifs of p300
induced by Ca
2+-ionophore affected the control of
MyHCI/b gene expression.
The two major p300 acetylation sites in NFATc1/aA
identiﬁed here are within the regulatory domain (K351)
and the Rel DNA binding domain (RSD; K549). We show
that acetylation at these sites can affect NFATc1 DNA
binding (Figure 7). The NFAT DNA binding domain is
very similar in its conformation to the Rel DNA binding
domain of Rel/NF-kB factors, and acetylation of the
RelA subunit by p300/CBP or PCAF (p300/CBP-
associated factor) at distinct sites either enhances or
diminishes DNA binding and regulates nuclear function
of NF-kB (75). Even though one acetylation site (K351)
on NFATc1 is not within the DNA binding domain it also
affects DNA binding. Likewise, p53 acetylation by p300
on multiple sites at the C-terminal regulatory domain
affects the function of its DNA binding domain in the
middle of the protein, presumably through conformation-
al changes (76,77). The exact underlying mechanism for
this effect remains unclear so far. It is reasonable that
acetylation at K351 can alter the conformation of
NFATc1 such that NFATc1 efﬁciently recruits the tran-
scriptional coactivator with concomitant increase in
complex stability. To conclude, changes in DNA binding
are involved in acetylation mediated increases in NFATc1
transactivation function. Our data do neither exclude a
role of other lysines for the transactivation function of
NFATc1/aA nor other possible effects of acetylation
like modulation of protein–protein interactions.
It is noteworthy that one acetylatable lysine and
adjacent amino acids (K351) in murine NFATc1 are
fully conserved across several different species and the
second acetylatable lysine (K549) and adjacent amino
acids are further conserved between NFATc1-4 family
members (Figure 7E). This suggests that NFAT acetyl-
ation by p300 at these sites might at least be part of a
general mechanism conserved in vertebrates. Although
we have studied the acetylation of NFATc1/aA in the
context of NFATc1-dependent MyHCI/b gene regulation
as a key event of slow ﬁber type-speciﬁc gene expression
upon increased intracellular Ca
2+ concentrations, it is con-
ceivable that NFATc1 isoforms and/or the other NFAT
family members in various tissues are similarly regulated
by acetylation and that such an event may also take place
in other biological processes, including NFAT roles in the
immune, nervous, vascular and endocrine systems, in
heart and in cancer progression (78).
Figure 9. Proposed model of the interaction of calcineurin-NFATc1, MEK1–ERK1/2 and p300signaling leading to slow skeletal muscle ﬁber-speciﬁc
gene expression. Stimuli that increase [Ca
2+]i result in translocation of dephosphorylated NFAT to the nucleus where it participates in mediating
Ca
2+-inducible gene expression of slow ﬁber genes, such as MyHCI/b. This induction of MyHCI/b can be further stimulated by Ca
2+-mediated
activation of the MEK1–ERK1/2 pathway resulting in the phosphorylation of transcriptional coactivator p300, leading to its recruitment to NFATc1
bound to the MyHCI/b promoter. Once recruited, phosphorylated p300 acetylates NFATc1 and enhances NFATc1–DNA binding. As a conse-
quence, p300 enhances gene expression of MyHCI/b mediated by increased intracellular Ca
2+-concentration. CaM, calmodulin; CKI/II, casein kinase
I/II; CsA, cyclosporine A; GSK3b, glycogensynthase kinase-3b: MCIP (myocyte-enriched calcineurin interacting protein).
5922 Nucleic Acids Research, 2011,Vol.39, No. 14In summary, interaction of the MEK1–ERK1/2
pathway with the transcriptional coactivator p300 was
found to play a key role in NFATc1-dependent MyHCI/
b promoter upregulation. The data presented here provide
a molecular basis for driving slow ﬁber-speciﬁc MyHCI/b
gene expression and point to a role of MEK1–ERK1/2
signaling in the regulation of muscle ﬁber type.
Consistent with our ﬁndings, (Ras-)MEK1/2-ERK signal-
ing has been shown to play a pivotal role in slow MyHCI/
b gene expression in regenerating rat soleus muscle (40)
and in rat primary skeletal muscle cells (79). Interestingly,
further studies in C2C12 and primary myotubes revealed
that Ca
2+-ionophore-induced activity of a fast MyHCIIa
promoter construct is also mediated by calcineurin/NFAT
and MEK1-dependent signaling (80), while another
MAPK, p38a/b, is essential for fast MyHCIId/x gene ex-
pression (81,82), and reduced p38a/b signaling is involved
in Ca
2+-ionophore-mediated MyHCIId/x downregulation
(81), whereas MEK1–ERK1/2 is not (data not shown). It
has been proposed earlier (83) that different subset of
genes are regulated by different signal transduction
pathways to achieve muscle ﬁber type-speciﬁc changes in
gene expression. In view of the data emerging so far, dif-
ferent signaling pathways can also converge to regulate
gene expression during fast-to-slow ﬁber type
transformation.
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